2024 International Symposium of Gastrointestinal Oncology (ISGIO)

Hitting the Target: Molecular Tumor Board With the Experts

Non-CE Product Theater

Current Status of Therapy for Well-Differentiated NETs

Medical Crossfire: Where Should We Incorporate Radioligand Therapy for Advanced NETs? PRRT Upfront

Medical Crossfire: Where Should We Incorporate Radioligand Therapy for Advanced NETs? Other Therapies First

Optimizing Chemotherapy Backbone in Metastatic PDAC Trials

Case Presentation: Novel Treatments for Localized HCC

Shifts in the Use of Multimodality Therapy for Localized HCC

Case Presentation: Systemic Therapy for Advanced HCC

How Do We Select the Best Therapy for Frontline Advanced HCC?

Hot Seat on Debatable Topics in Biliary Tract Cancer

Non-CME Product Theater: Expanding Options in 1L Metastatic Pancreatic Cancer

Case Presentation: Contemporary Challenges in Non-Metastatic EG Cancer

2024 Highlights and Principles for Management of Non-Metastatic EG Cancers

Case Presentation: Contemporary Challenges in Metastatic EG Cancer

2024 Highlights and Principles for Management of Metastatic EG Cancers

Non-CE Symposium Breakfast: Evolving Biomarker Landscape in Gastric and Gastroesophageal Junction Adenocarcinomas

Multidisciplinary Management of Locally Advanced Rectal Cancer

Where We Stand in 2024 Using ctDNA for Colon Cancer

Case 1: MSI-H Local Colon Cancer, Considerations for Nonoperative Management

Case 2: Immunotherapy for Localized Rectal Cancer

Non-CE Product Theater: The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade

Immunotherapy in MSS CRC: What Has Changed in 2024?

What's Coming in Targeted Therapy for Advanced CRC?

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? Case Presentation

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? One Drug

Medical Crossfire Debate: Should 2 Drugs or 1 Drug Be the Standard of Care for MSI-H mCRC? Two Drugs